

World Journal of *Clinical Oncology*

World J Clin Oncol 2024 February 24; 15(2): 165-359



EDITORIAL

- 165 Circulating tumor cells as prognostic marker in pancreatic cancer
Yakar M, Etiz D
- 169 Unlocking the potential-vitamin D in prostate cancer prevention
Cassell A, Konneh S
- 175 TM9SF1 is implicated in promoting the proliferation and invasion of bladder cancer cells
Zhou SQ, Luo LX

REVIEW

- 178 Updates on management of gliomas in the molecular age
Mohamed AA, Alshabi R, Faragalla S, Mohamed Y, Lucke-Wold B

MINIREVIEWS

- 195 Deregulation of interferon-gamma receptor 1 expression and its implications for lung adenocarcinoma progression
Tecalco-Cruz AC, Medina-Abreu KH, Oropeza-Martínez E, Zepeda-Cervantes J, Vázquez-Macias A, Macias-Silva M

ORIGINAL ARTICLE**Clinical and Translational Research**

- 208 Elucidating the molecular basis of ATP-induced cell death in breast cancer: Construction of a robust prognostic model
Zhang HL, Doblin S, Zhang ZW, Song ZJ, Dinesh B, Tabana Y, Saad DS, Adam Ahmed Adam M, Wang Y, Wang W, Zhang HL, Wu S, Zhao R, Khaled B
- 243 Identification of immune cell-related prognostic genes characterized by a distinct microenvironment in hepatocellular carcinoma
Li MT, Zheng KF, Qiu YE
- Retrospective Study**
- 271 Population-based X-ray gastric cancer screening in Hiroshima prefecture, Japan
Vu NTH, Urabe Y, Quach DT, Oka S, Hiyama T
- 282 Endoscopic resection for calcifying fibrous tumors of the gastrointestinal tract
Geng ZH, Zhu Y, Fu PY, Qu YF, Chen SY, Zhong YS, Zhang YQ, Chen WF, Qin WZ, Hu JW, Cai MY, Yao LQ, Li QL, Zhou PH

Observational Study

- 290 Prevalence, risk factors, and BRAF mutation of colorectal sessile serrated lesions among Vietnamese patients
Vu NTH, Le HM, Vo DTN, Vu HA, Le NQ, Ho DDQ, Quach DT

Basic Study

- 302 TM9SF1 promotes bladder cancer cell growth and infiltration
Wei L, Wang SS, Huang ZG, He RQ, Luo JY, Li B, Cheng JW, Wu KJ, Zhou YH, Liu S, Li SH, Chen G
- 317 Limonin inhibits the stemness of cancer stem-like cells derived from colorectal carcinoma cells potentially via blocking STAT3 signaling
Zhang WF, Ruan CW, Wu JB, Wu GL, Wang XG, Chen HJ

META-ANALYSIS

- 329 Identification and validation of a pyroptosis-related prognostic model for colorectal cancer based on bulk and single-cell RNA sequencing data
Zhu LH, Yang J, Zhang YF, Yan L, Lin WR, Liu WQ

LETTER TO THE EDITOR

- 356 Bridging the gap: Predicting brain metastasis in breast cancer
Gonsalves D, Ciérvide R, Couñago F

ABOUT COVER

Peer Reviewer of *World Journal of Clinical Oncology*, Arkadeep Dhali, MBBS, MPH, FRSPH, Academic Clinical Fellow, Academic Unit of Gastroenterology, Sheffield Teaching Hospitals, Sheffield, United Kingdom.
arkadipdhali@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Oncology* (*WJCO*, *World J Clin Oncol*) is to provide scholars and readers from various fields of oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJCO mainly publishes articles reporting research results and findings obtained in the field of oncology and covering a wide range of topics including art of oncology, biology of neoplasia, breast cancer, cancer prevention and control, cancer-related complications, diagnosis in oncology, gastrointestinal cancer, genetic testing for cancer, gynecologic cancer, head and neck cancer, hematologic malignancy, lung cancer, melanoma, molecular oncology, neurooncology, palliative and supportive care, pediatric oncology, surgical oncology, translational oncology, and urologic oncology.

INDEXING/ABSTRACTING

The *WJCO* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJCO* as 2.8; IF without journal self cites: 2.8; 5-year IF: 3.0; Journal Citation Indicator: 0.36.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Xiang-Di Zhang; Production Department Director: Xu Guo; Editorial Office Director: Xu Guo.

NAME OF JOURNAL

World Journal of Clinical Oncology

ISSN

ISSN 2218-4333 (online)

LAUNCH DATE

November 10, 2010

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Hiten RH Patel, Stephen Safe, Jian-Hua Mao, Ken H Young

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2218-4333/editorialboard.htm>

PUBLICATION DATE

February 24, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

TM9SF1 is implicated in promoting the proliferation and invasion of bladder cancer cells

Shu-Qing Zhou, Lian-Xiang Luo

Specialty type: Cell biology

Provenance and peer review:

Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Chen BH, Taiwan

Received: December 9, 2023

Peer-review started: December 9, 2023

First decision: December 18, 2023

Revised: December 27, 2023

Accepted: January 30, 2024

Article in press: January 30, 2024

Published online: February 24, 2024



Shu-Qing Zhou, The First Clinical College, Guangdong Medical University, Zhanjiang 524023, Guangdong Province, China

Lian-Xiang Luo, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang 524000, Guangdong Province, China

Corresponding author: Lian-Xiang Luo, PhD, Associate Professor, The Marine Biomedical Research Institute, Guangdong Medical University, No. 2 East Wenming Road, Zhanjiang 524000, Guangdong Province, China. luolianxiang321@gdmu.edu.cn

Abstract

Zhuo *et al* looked into the part of transmembrane 9 superfamily member 1 (TM9SF1) in bladder cancer (BC), and evaluated if it can be used as a therapeutic target. They created a permanent BC cell line and tested the effects of TM9SF1 overexpression and suppression on BC cell growth, movement, invasion, and cell cycle advancement. Their results show that TM9SF1 can boost the growth, movement, and invasion of BC cells and their access into the G2/M stage of the cell cycle. This research gives a novel direction and concept for targeted therapy of BC.

Key Words: Bladder cancer; TM9SF1; Cell proliferation; Migration; Invasion; TM9SF1 overexpression; TM9SF1 silencing inhibits

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The transmembrane 9 superfamily member (TM9SF) TM9SF family's biological function has not been investigated yet. However, some studies have suggested that its expression could be associated with the emergence and progression of tumors. This article used various experimental methods, such as CCK8, wound healing test, transwell test, and flow cytometry, to explore the effect of TM9SF1 on the biological behavior of bladder cancer (BC), in order to offer a novel approach for the treatment of BC.

Citation: Zhou SQ, Luo LX. TM9SF1 is implicated in promoting the proliferation and invasion of bladder cancer cells. *World J Clin Oncol* 2024; 15(2): 175-177

URL: <https://www.wjgnet.com/2218-4333/full/v15/i2/175.htm>

DOI: <https://dx.doi.org/10.5306/wjco.v15.i2.175>

INTRODUCTION

Bladder cancer has a high recurrence rate and is resistant to chemotherapy[1-4]. The most prominent symptom of bladder cancer (BC) is microscopic or visually visible hematuria, and 75% of bladder tumors are uroepithelial carcinomas limited to mucous membranes, *i.e.*, non-muscular aggressive BC (NMIBC)[5-8]. Approximately 80% of bladder cancers are superficial papillary lesions caused by urothelial hyperplasia, which are of low grade and may recur, but rarely invade the bladder wall or metastasize. The remaining 15%-20% are high-grade solid non-papillary BC, which is caused by high-grade intraepithelial urothelial neoplasia, which has a high tendency to spread far. Most bladder cancers (75%-80%) do not involve the bladder muscle wall and are usually treated with transurethral resection of bladder tumor, however, many BC patients have poor prognosis and poor long-term survival[9,10]. So, the treatment of bladder cancer needs to go further.

By establishing an effective prognostic nomogram model for esophageal squamous cell carcinoma, two marker genes were identified that are directly associated with 4-year overall survival of cancer patients, one of which is TM9SF1. The expression value of TM9SF1 gene in cancer patients was found to be significantly higher than that of healthy individuals [11]. ApostolosZaravinos' study employed genome-wide microarray analysis, classifying samples based on histology and discovering 17 differentially expressed genes, one of which was TM9SF1. This discovery makes it more necessary and possible to investigate the role of TM9SF1 in cancer, as well as its effects and mechanisms on bladder cancer cells[12]. TM9SF1, identified as an estrogen receptor binding fragment-associated antigen 9 (EBAG9) interaction factor, and EBAG9 have been observed to act in harmony to control the migration of prostate cancer cells by influencing genes associated with epithelial-mesenchymal transition. This is in line with the study in this paper that the overexpression of TM9SF1 can promote the migration of BC cells[13]. Zhuo *et al*[14] have discovered that TM9SF1, a transmembrane 9 superfamily member 1, is a functional mRNA target of phosphorylated CTD interaction factor 1 (PCIF1). This gene acts as a tumor suppressor in cancer, with PCIF1 using m6Am to modify the TM9SF1 mRNA, which in turn reduces its translation. It has been found that TM9SF1 can reverse the effect of PCIF1 on the aggressiveness of cancer cells, suggesting different functions and roles in different tumor types. Zhuo *et al*[14] conducted further research to determine the role of TM9SF1 overexpression and silencing in three cell lines (5637, T24, and UMUC-3). Through CCK8, wound healing test, cross-well migration test and separation of high - and low-nutrient protein sets, TM9SF1 was identified as an oncogene in BC. When TM9SF1 was silenced, it suppressed the growth and motility of BC cells *in vitro*. Overexpression of TM9SF1, on the other hand, was found to increase the proliferation of BC cells and enhance their migration and invasion abilities. This opens up the possibility of new treatments for BC.

CONCLUSION

This editorial has demonstrated that TM9SF1, a member of the transmembrane 9 superfamily, could be used as a biomarker for bladder cancer treatment, thus offering a fresh approach to treating the condition.

FOOTNOTES

Author contributions: Luo LX conceived and designed the editorial; Zhou SQ wrote the editorial; Luo LX reviewed the paper and provided comments; All authors read and approved the final manuscript.

Conflict-of-interest statement: All the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Lian-Xiang Luo 0000-0002-3391-9713.

S-Editor: Liu JH

L-Editor: A

P-Editor: Zhang XD

REFERENCES

- 1 **Matuszczak M**, Kiljańczyk A, Salagierski M. A Liquid Biopsy in Bladder Cancer-The Current Landscape in Urinary Biomarkers. *Int J Mol Sci* 2022; **23** [PMID: 35955727 DOI: 10.3390/ijms23158597]
- 2 **Chang CH**, Lin BJ, Chen CH, Nguyen NL, Hsieh TH, Su JH, Chen MC. Stelletin B Induces Cell Death in Bladder Cancer Via Activating the Autophagy/DAPK2/Apoptosis Signaling Cascade. *Mar Drugs* 2023; **21** [PMID: 36827114 DOI: 10.3390/md21020073]
- 3 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]
- 4 **Afonso J**, Santos LL, Longatto-Filho A, Baltazar F. Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. *Nat Rev Urol* 2020; **17**: 77-106 [PMID: 31953517 DOI: 10.1038/s41585-019-0263-6]
- 5 **Tran L**, Xiao JF, Agarwal N, Duex JE, Theodorescu D. Advances in bladder cancer biology and therapy. *Nat Rev Cancer* 2021; **21**: 104-121 [PMID: 33268841 DOI: 10.1038/s41568-020-00313-1]
- 6 **Zhu S**, Yu W, Yang X, Wu C, Cheng F. Traditional Classification and Novel Subtyping Systems for Bladder Cancer. *Front Oncol* 2020; **10**: 102 [PMID: 32117752 DOI: 10.3389/fonc.2020.00102]
- 7 **Berdik C**. Unlocking bladder cancer. *Nature* 2017; **551**: S34-S35 [PMID: 29117159 DOI: 10.1038/551S34a]
- 8 **Funt SA**, Rosenberg JE. Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. *Nat Rev Clin Oncol* 2017; **14**: 221-234 [PMID: 27874062 DOI: 10.1038/nrclinonc.2016.188]
- 9 Bladder cancer: diagnosis and management of bladder cancer: © NICE (2015) Bladder cancer: diagnosis and management of bladder cancer. *BJU Int* 2017; **120**: 755-765 [PMID: 29168333 DOI: 10.1111/bju.14045]
- 10 **Charlton ME**, Adamo MP, Sun L, Deorah S. Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004-2010. *Cancer* 2014; **120** Suppl 23: 3815-3825 [PMID: 25412393 DOI: 10.1002/cncr.29047]
- 11 **Liu K**, Jiao YL, Shen LQ, Chen P, Zhao Y, Li MX, Gu BL, Lan ZJ, Ruan HJ, Liu QW, Xu FB, Yuan X, Qi YJ, Gao SG. A Prognostic Model Based on mRNA Expression Analysis of Esophageal Squamous Cell Carcinoma. *Front Bioeng Biotechnol* 2022; **10**: 823619 [PMID: 35299644 DOI: 10.3389/fbioe.2022.823619]
- 12 **Zaravinos A**, Lambrou GI, Boulalas I, Delakas D, Spandidos DA. Identification of common differentially expressed genes in urinary bladder cancer. *PLoS One* 2011; **6**: e18135 [PMID: 21483740 DOI: 10.1371/journal.pone.0018135]
- 13 **Miyazaki T**, Ikeda K, Sato W, Horie-Inoue K, Inoue S. Extracellular vesicle-mediated EBAG9 transfer from cancer cells to tumor microenvironment promotes immune escape and tumor progression. *Oncogenesis* 2018; **7**: 7 [PMID: 29362448 DOI: 10.1038/s41389-017-0022-6]
- 14 **Zhuo W**, Sun M, Wang K, Zhang L, Li K, Yi D, Li M, Sun Q, Ma X, Liu W, Teng L, Yi C, Zhou T. m(6)Am methyltransferase PCIF1 is essential for aggressiveness of gastric cancer cells by inhibiting TM9SF1 mRNA translation. *Cell Discov* 2022; **8**: 48 [PMID: 35597784 DOI: 10.1038/s41421-022-00395-1]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: office@baishideng.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

